Andrew Saik, the Chief Financial Officer of $ARVN, sold 5,700 shares of the company on 06-24-2025 for an estimated $43,377. We received data on the trade from a ...

Arvinas, Inc. (ARVN) closed the last trading session at $7.50, gaining 3.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall ...

Fintel reports that on June 2, 2025, Leerink Partners downgraded their outlook for Arvinas (NasdaqGS:ARVN) from Outperform to Market Perform. Analyst Price Forecast Suggests 103.41% Upside As of June ...

Fintel reports that on October 15, 2025, Goldman Sachs downgraded their outlook for Arvinas (NasdaqGS:ARVN) from Neutral to Sell. Analyst Price Forecast Suggests 30.07% Upside As of September 30, 2025 ...

NEW YORK, NY / ACCESS Newswire / May 10, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Arvinas, Inc. ("Arvinas") (NASDAQ:ARVN) concerning possible violations of ...

All right, everyone. I think we'll get started here with the afternoon session. My name is Derek Archila. I'm one of the Wells Fargo biotech analysts. Very excited to have the Arvinas team here. From ...

Arvinas shows strong ESR1-mutant data with limited scope, niche SERD competition, Pfizer uncertainty, and a high-risk pipeline. See why ARVN stock is a hold.

On May 1, 2025, Arvinas and its partner Pfizer announced that they would discontinue development of vepdegestrant, an oral SERD for HR-positive breast cancer. The move eliminated two planned Phase 3 ...

Sept 17 (Reuters) - Drug developer Arvinas (ARVN.O), opens new tab said on Wednesday it will grant commercialization rights of an experimental breast cancer treatment it was developing with Pfizer ...